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Voriconazole is a treatment for severe fungal infections. Prolonged voriconazole therapy may induce skin reactions, with 1%
of severe photosensitivity accidents. Recently the imputability of voriconazole in skin carcinogenesis has been suggested. This
report concerns a 55-year-old man suﬀering from pulmonary aspergillosis who presented a phototoxic reaction a few months
after introduction of voriconazole, followed by multiple squamous cell carcinomas of sun-exposed skin areas. After voriconazole
discontinuation, no new carcinoma was observed. The detection of EBV and HPV in skin lesions was negative. Exploration of
gene mutations involved in skin carcinogenesis showed two variants of the MICR gene. The occurrence of multiple, recurrent,
aggressive squamous cell carcinomas is rare with voriconazole,but its imputability is strongly suggested. A plausible hypothesis is
that several factors including voriconazole uptake, immunosuppression, and genetic background could explain the phenotype of
fast-developingskincarcinomas.Voriconazoletherapy shouldbe accompaniedby stringentphotoprotection andskinmonitoring.
1.Introduction
Voriconazole, a new broad-spectrum triazole antifungal
agent, was approved by the US Food and Drug Administra-
tion in May 2002. Its use has increased steadily because of its
high eﬀectiveness against a wide variety of yeasts and molds
and its excellent oral bioavailability [1]. The most common
side eﬀects reported are visual disturbances, elevation in
hepatic enzyme levels, and rashes [2, 3]. Photosensitivity
reactions of varying severity are frequent (1%) and well doc-
umented [4–6]. In contrast, only 16 cases of squamous cell
carcinomas have been reported, characterized by clinical
severity [7–11].
We report a new case of phototoxicity associated with
multiple squamous cell carcinomas in a patient treated for 2
years using voriconazole. We discuss the possible mecha-
nisms induced by voriconazole, a photosensitizing drug, in
skin carcinogenesis.
2.Case Presentation
A man of 55 had been treated with corticosteroids
(10mg/day) for sarcoidosis since 1974. In February 2004,
treatment comprising 200mg voriconazole twice daily was
instated for pulmonary aspergillosis in this setting of im-
munosuppression. His usual treatment consisted of salbu-
tamol, budesonide, and ramipril. He had a Fitzpatrick skin
phototype II and was living in a temperate area. He was an
oﬃce worker and had never had intensive, prolonged sun-
exposure. No previous personal or familial skin cancer was
noted.
In May 2004, four months after the voriconazole instate-
ment, a photo-exposure erythema appeared on the face,
scalp, and backs of hands, with several relapses. In August
2006, while the patient was still receiving voriconazole,
multipleerosiveand keratosiclesionsofphoto-exposed areas
appeared, associated with erythema of the back of hands2 Case Reports in Medicine
(Figure 1(a)). To characterize the photoreaction, phototests
were performed. UVA minimum erythema dose (MED) was
normal,and UVB-MEDwasslightlylowered(46,20mJ/cm2;
N > 50mJ/cm2).Photopatch-testsperformed inthehypoth-
esis of a photoallergy were negative. These results argued
for a phototoxic rather than a photoallergic photosensitive
reaction.
The lesions worsened, becoming inﬁltrated and crusted.
The ﬁrst biopsy on the face in May 2007 showed a microin-
vasive squamous cell carcinoma. Subsequently, 17 squamous
cell carcinomas and multiple actinic keratoses (Figures 1(b)
and 1(c))o nt h ef a c ea n ds c a l pw e r ed i a g n o s e du pt o
December 2008 at which time voriconazole was discon-
tinued. Between January and December 2009, actinic ker-
atoses were observed, but no carcinoma. Both curative and
preventive treatments associating imiquimod, cryotherapy,
photodynamic therapy, and surgery by excision-graft of
micro-invasive carcinomas were implemented.
Using in situ hybridation we tested for Epstein-Barr-
Encoded-small-RNAs- (EBERs-) positive cells with EBV-
encoded RNA 1 oligonucleotide probe (Benchmark XT
automat, Ventana), and for human papillomavirus using
reagents and INFORM HPV III Family 16 DNA Probe
(B) (P/N 800-4295) (Ventana Medical Systems Inc.), in the
cutaneous lesions. No EBV or HPV infection was detected.
Given the phenotype of the multiple skin carcino-
mas, a search for DNA mutations in genes involved in
predisposition to cutaneous carcinoma (MC1R, POLH)
was performed. After signature of informed consent and
obtaining blood samples, DNA extraction was performed,
followed by ampliﬁcation using PCR primers speciﬁc to the
coding exons, ﬂanking intrinsic sequences, and automated
sequencing (Applied Biosystems 3130R). No mutation of the
POLH (XPV) gene, involved in xeroderma pigmentosum
variant, was detected, but two variants of the MC1R gene,
Arg151Cys and Ser131Asn, were characterized. The ﬁrst
is a well-known loss of function in the MC1R variant
that is associated with both the RHC (Red Hair Color)
phenotype and an increased risk of skin cancer. The second
variant, S131N, has not been previously described, to our
knowledge; it occurs at a highly conserved residue and
is predicted to be deleterious genomic mutation (SIFT,
Polyphen).
3.Discussion
Voriconazole, a broad-spectrum azole antifungal agent,
inhibits the cytochrome P450-dependent 14α-lanosterol
demethylation, an essential step in fungal cell membrane
ergosterol synthesis [1, 3]. It is indicated in diﬀerent
fungal infections, particularly invasive aspergillosis [3]. This
molecule is easily used by oral route with excellent bioavail-
ability. It is therefore widely prescribed. However, signiﬁcant
side eﬀects have been reported, with 30% visual distur-
bances, 10% liver abnormalities, and 8.6% skin reactions
[1–3].
Among adverse cutaneous drug reactions, cases of gener-
alized erythema, eczema, urticaria, bullous lichen, erythema
multiform (0.05%), or Lyell’s syndrome (0.1%) have been
reported [1–3]. Photosensitivity, idiosyncratic rather than
dose-dependent, is described in 1% of subjects and appears
in prolonged treatment (at least 12 weeks). In most cases,
skin reactions disappear on an average of 4 weeks after
voriconazole discontinuation [4, 5, 12, 13].
Inparticular, as inthis case report, 15patientspresenting
multiple squamous carcinomas have been recently reported
in three cases and two series [7–11]. These 15 patients
and the present case developed a phototoxic rash on sun-
exposed areas on an average of 6.56 months after starting
treatment (15 days to 15 months). The actinic keratoses and
squamous cell carcinomas that appeared after an average of
28 months of treatment (12 to 36 months) were multiple.
Skin carcinoma onset occurred at a mean age of 38 years
(9 to 69 years), much earlier compared to the average age
for occurrence of these lesions in the general population
(76 years) [14]. Among these 16 patients, voriconazole
discontinuation led to photosensitivity regression from day
14 for 7 patients and data were unavailable for 9 patients. No
newcarcinomahadoccurredfor4patientsat10monthsafter
voriconazole discontinuation, and data were unavailable for
12 patients.
Immunosuppression, present in all patients treated with
voriconazole, could be expected to induce these squamous
cell carcinomas, as in transplant patients [15]. In the setting
of immuno-suppression, EBV and HPV have also been
implicated in development of nonmelanoma skin cancer
[16–18]. In our case, EBV or HPV infection in skin lesions
was not detected.
The absence of new squamous cell carcinomas con-
comitant with the interruption of voriconazole suggests its
causal role, especially given its phototoxicity. Two mecha-
nisms are suggested in voriconazole phototoxicity: (i) direct
phototoxicity by voriconazole or its metabolites, and (ii)
a retinoid-like mechanism [4, 13]. Like ﬂuoroquinolones,
which are also phototoxic molecules, voriconazole may
amplify local, systemic immuno-suppression [19]a n dt h e
genotoxicity [20] induced by UV. An ampliﬁcation of
immuno-suppression bylocalenhancementoftheinhibitory
eﬀect on immuno-competent cells has been shown for ﬂu-
oroquinolones [21]. Concerning genotoxicity, it has been
reported, in an experimental model, that ﬂuoroquinolones,
especially lomeﬂoxacin and ﬂeroxacin, associated with UVA
radiation, enhanced tumor prevalence and drastically short-
enedthemedianlatentperiodoftumoronsetcomparedwith
UVA alone [22–24]. In UV-irradiated xeroderma pigmen-
tosum group A gene-deﬁcient mice, defective in nucleotide
excision repair, the treatment with lomeﬂoxacin induced
DNA damage [25]. In our case, no mutation of POLH,
a gene predisposing to xeroderma pigmentosum variant,
was identiﬁed. However, two MC1R functional variants,
Arg151Cys and Ser131Asn, were identiﬁed. These variants
have been shown to be involved in basal and squamous cell
carcinoma [26].
A plausible hypothesis is that several factors including
voriconazole uptake, immuno-suppression, and the genetic
background(MC1Rvariants)couldexplainthephenotypeof
proliferating multiple skin carcinomas.Case Reports in Medicine 3
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Figure 1: (a) Actinic keratosis and multiple squamous cell carcinomas of photo-exposed areas induced by voriconazole. (b) Microinvasive
squamouscellcarcinoma.Epithelialproliferationcomposedofatypicalkeratinocytes inﬁltratingthedermis,magniﬁcation×200.(c)Actinic
keratosis hyperkeratosis, slightly atypical epidermal hyperplasia; magniﬁcation ×200.4 Case Reports in Medicine
4.Conclusion
Voriconazole, a new antifungal agent, is attractive by its
eﬃciency and ease of use. However, our case and others
in the literature suggest that prolonged treatments, in a
context of immunosuppression complicated by phototoxic-
ity reactions, can predispose to risk of multiple recurrent,
aggressive squamous cell carcinomas. In patients at risk, an
alternative therapy should be discussed whenever possible.
Dermatological supervision, stringent measures of external
photoprotection, and sun avoidance are recommended.
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